Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Addex Therapeutics (ADXN) Current Assets (2018 - 2025)

Addex Therapeutics' Current Assets history spans 8 years, with the latest figure at $2.1 million for Q4 2025.

  • On a quarterly basis, Current Assets fell 48.0% to $2.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.1 million, a 48.0% decrease, with the full-year FY2025 number at $2.0 million, down 49.87% from a year prior.
  • Current Assets came in at $2.1 million for Q4 2025, down from $3.0 million in the prior quarter.
  • The five-year high for Current Assets was $29.1 million in Q1 2021, with the low at $2.1 million in Q4 2025.
  • Historically, Current Assets has averaged $10.2 million across 5 years, with a median of $7.0 million in 2023.
  • Biggest five-year swings in Current Assets: increased 10.38% in 2021 and later plummeted 65.85% in 2022.
  • Year by year, Current Assets stood at $23.8 million in 2021, then crashed by 65.85% to $8.1 million in 2022, then crashed by 41.26% to $4.8 million in 2023, then dropped by 15.32% to $4.0 million in 2024, then crashed by 48.0% to $2.1 million in 2025.
  • Business Quant data shows Current Assets for ADXN at $2.1 million in Q4 2025, $3.0 million in Q3 2025, and $3.2 million in Q2 2025.